Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAT2 | Q10469 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | MOGAT2 | Q3SYC2 | 8/20 | 0.39 |
| ▸ | APP | P05067 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | BRD4 | O60885 | 5/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13545310 | 0.80 | HTR6 (0.36) | MGAT2HTR6APPMAPTBRD4 | |
| SCHEMBL3596379 | 0.77 | MGAT2 (0.37) | MGAT2MOGAT2MAPTBRD4ALDH1A1 | |
| SCHEMBL7170898 | 0.77 | CSNK1G1 (0.45) | MGAT2MAPTBRD4ALDH1A1HSD17B10 | |
| SCHEMBL3596380 | 0.75 | CA9 (0.40) | MGAT2HTR6MOGAT2MAPTRECQL | |
| SCHEMBL23346087 | 0.75 | — | — | |
| SCHEMBL13545349 | 0.74 | PDK2 (0.52) | HTR6IDO1 | |
| SCHEMBL14566623 | 0.74 | PDK2 (0.52) | IDO1 | |
| SCHEMBL13382907 | 0.72 | HTR6 (0.37) | HTR6IDO1ARALDH1A1RECQL | |
| SCHEMBL757520 | 0.71 | PDK2 (0.52) | MGAT2MAPTBRD4ALDH1A1HSD17B10 | |
| SCHEMBL29789747 | 0.71 | PDK2 (0.52) | MGAT2MAPTBRD4ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010038803-A1 | 2-INDOLEACRYLAMIDE ANALOGUE | 持田製薬株式会社 (JP) | 2010-04-08 | — | — | WO | disclosed |
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | MGAT2 1988/4885HTR6 1987/4885MOGAT2 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.